100 related articles for article (PubMed ID: 15207753)
41. Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies.
Rogers A; Clowes JA; Pereda CA; Eastell R
Bone; 2007 Jan; 40(1):105-10. PubMed ID: 16934544
[TBL] [Abstract][Full Text] [Related]
42. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
[TBL] [Abstract][Full Text] [Related]
43. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
44. Susceptibility to Fas and tumor necrosis factor-alpha receptor mediated apoptosis of anti-CD3/anti-CD28-activated umbilical cord blood T cells.
Lin SJ; Lee CC; Cheng PJ; See LC; Kuo ML
Pediatr Allergy Immunol; 2009 Jun; 20(4):392-8. PubMed ID: 18713315
[TBL] [Abstract][Full Text] [Related]
45. High molecular weight plasma proteins induce apoptosis and Fas/FasL expression in human proximal tubular cells.
Morais C; Westhuyzen J; Metharom P; Healy H
Nephrol Dial Transplant; 2005 Jan; 20(1):50-8. PubMed ID: 15522900
[TBL] [Abstract][Full Text] [Related]
46. Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha.
Habib HM; Taher TE; Isenberg DA; Mageed RA
Scand J Rheumatol; 2009; 38(2):112-20. PubMed ID: 19110660
[TBL] [Abstract][Full Text] [Related]
47. Mechanism of Fas-mediated cell death and its enhancement by TNF-alpha in human salivary gland adenocarcinoma cell line HSG.
Chosa N; Kyakumoto S; Kito N; Kamo M; Sato N
Eur J Oral Sci; 2004 Aug; 112(4):338-46. PubMed ID: 15279653
[TBL] [Abstract][Full Text] [Related]
48. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
Xue C; Lan-Lan W; Bei C; Jie C; Wei-Hua F
Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
[TBL] [Abstract][Full Text] [Related]
49. Estradiol increases apoptosis in human coronary artery endothelial cells by up-regulating Fas and Fas ligand expression.
Seli E; Guzeloglu-Kayisli O; Cakmak H; Kayisli UA; Selam B; Arici A
J Clin Endocrinol Metab; 2006 Dec; 91(12):4995-5001. PubMed ID: 17003091
[TBL] [Abstract][Full Text] [Related]
50. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol.
Song RX; Mor G; Naftolin F; McPherson RA; Song J; Zhang Z; Yue W; Wang J; Santen RJ
J Natl Cancer Inst; 2001 Nov; 93(22):1714-23. PubMed ID: 11717332
[TBL] [Abstract][Full Text] [Related]
51. TNFalpha down-regulates the Fas ligand and inhibits germ cell apoptosis in the human testis.
Pentikäinen V; Erkkilä K; Suomalainen L; Otala M; Pentikäinen MO; Parvinen M; Dunkel L
J Clin Endocrinol Metab; 2001 Sep; 86(9):4480-8. PubMed ID: 11549697
[TBL] [Abstract][Full Text] [Related]
52. Estradiol and raloxifene induce the proliferation of osteoblasts through G-protein-coupled receptor GPR30.
Noda-Seino H; Sawada K; Hayakawa J; Ohyagi-Hara C; Mabuchi S; Takahashi K; Nishio Y; Sakata M; Kurachi H; Kimura T
J Endocrinol Invest; 2013 Jan; 36(1):21-7. PubMed ID: 22453024
[TBL] [Abstract][Full Text] [Related]
53. Effects of the selective estrogen receptor modulator LY117018 on growth hormone secretion: In vitro studies.
Tulipano G; Bonfanti C; Poiesi C; Burattin A; Turazzi S; Barone G; Cozzi R; Bollati A; Valle D; Giustina A
Metabolism; 2004 May; 53(5):563-70. PubMed ID: 15131758
[TBL] [Abstract][Full Text] [Related]
54. Dexamethasone affects Fas- and serum deprivation-induced cell death of human osteoblastic cells through survivin regulation.
Rippo MR; Villanova F; Tomassoni Ardori F; Graciotti L; Amatori S; Manzotti S; Fanelli M; Gigante A; Procopio A
Int J Immunopathol Pharmacol; 2010; 23(4):1153-65. PubMed ID: 21244764
[TBL] [Abstract][Full Text] [Related]
55. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival.
Krum SA; Miranda-Carboni GA; Hauschka PV; Carroll JS; Lane TF; Freedman LP; Brown M
EMBO J; 2008 Feb; 27(3):535-45. PubMed ID: 18219273
[TBL] [Abstract][Full Text] [Related]
56. Expression and function of TNF-family proteins and receptors in human osteoblasts.
Bu R; Borysenko CW; Li Y; Cao L; Sabokbar A; Blair HC
Bone; 2003 Nov; 33(5):760-70. PubMed ID: 14623051
[TBL] [Abstract][Full Text] [Related]
57. ERα signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis.
Garcia AJ; Tom C; Guemes M; Polanco G; Mayorga ME; Wend K; Miranda-Carboni GA; Krum SA
J Bone Miner Res; 2013 Feb; 28(2):283-90. PubMed ID: 22927007
[TBL] [Abstract][Full Text] [Related]
58. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice.
Erlandsson MC; Jonsson CA; Lindberg MK; Ohlsson C; Carlsten H
J Endocrinol; 2002 Nov; 175(2):319-27. PubMed ID: 12429030
[TBL] [Abstract][Full Text] [Related]
59. A novel nongenomic action of estrogens: the regulation of exocytotic kinetics.
Machado JD; Alonso C; Morales A; Borges R
Ann N Y Acad Sci; 2002 Oct; 971():284-6. PubMed ID: 12438136
[No Abstract] [Full Text] [Related]
60. Rivaroxaban significantly inhibits the stimulatory effects of bone-modulating hormones: In vitro study of primary female osteoblasts.
Somjen D; Sharfman ZT; Katzburg S; Sharon O; Maman E; Salai M; Stern N; Dolkart O
Connect Tissue Res; 2017 Mar; 58(2):215-220. PubMed ID: 27661794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
